The long-acting phosphodiesterase inhibitor tadalafil does not influence athletes' V̇O2max, aerobic, and anaerobic thresholds in normoxia

Luigi Di Luigi, C. Baldari, F. Pigozzi, G. P. Emerenziani, M. C. Gallotta, F. Iellamo, E. Ciminelli, P. Sgrò, F. Romanelli, A. Lenzi, L. Guidetti

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Whereas experimental studies showed that in healthy trained subjects, the phosphodiesterase-5 inhibitor (PDE-5i) sildenafil improves exercise capacity in hypoxia and not in normoxia, no studies on the effects of the long half-life PDE-5i tadalafil exist. In order to evaluate whether tadalafil influences functional parameters and performance during a maximal exercise test in normoxia, we studied 14 healthy male athletes in a double-blind cross-over protocol. Each athlete performed two tests on a cycle ergometer, both after placebo or tadalafil (at therapeutic dose: 20 mg) administration. Oxygen consumption (V̇O2), blood lactate, respiratory exchange ratio, rate of perceived exertion, arterial blood pressure (BP), heart frequency (HR) and oxygen pulse (V̇O2/HR) were evaluated before exercise, at individual ventilatory and anaerobic thresholds (IVT and IAT), at V̇O 2max and during recovery. Compared to placebo, a single tadalafil administration significantly reduced systolic BP before and after exercise (p <0.05), decreased V̇O2/HR at IVT (13.3 ± 1.8 vs. 14.5 ± 2.1 mL·beat-1; p = 0.03), but did not modify individual V̇O2max, IVT, or IAT. In healthy athletes, 20 mg of tadalafil does not substantially influence physical fitness-related parameters, exercise tolerance, and cardiopulmonary responses to maximal exercise in normoxia; it remains to be verified if higher doses/prolonged use influence health and/or sport performance in field conditions.

Original languageEnglish
Pages (from-to)110-115
Number of pages6
JournalInternational Journal of Sports Medicine
Volume29
Issue number2
DOIs
Publication statusPublished - Feb 2008

Fingerprint

Anaerobic Threshold
Phosphodiesterase Inhibitors
Athletes
Exercise
Phosphodiesterase 5 Inhibitors
Placebos
Blood Pressure
Athletic Performance
Exercise Tolerance
Physical Fitness
Exercise Test
Oxygen Consumption
Half-Life
Lactic Acid
Healthy Volunteers
Arterial Pressure
Tadalafil
Oxygen
Health

Keywords

  • Doping
  • Erectile dysfunction
  • Exercise
  • Nitric oxide
  • PDE-5
  • Sport

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health
  • Orthopedics and Sports Medicine
  • Physical Therapy, Sports Therapy and Rehabilitation

Cite this

The long-acting phosphodiesterase inhibitor tadalafil does not influence athletes' V̇O2max, aerobic, and anaerobic thresholds in normoxia. / Di Luigi, Luigi; Baldari, C.; Pigozzi, F.; Emerenziani, G. P.; Gallotta, M. C.; Iellamo, F.; Ciminelli, E.; Sgrò, P.; Romanelli, F.; Lenzi, A.; Guidetti, L.

In: International Journal of Sports Medicine, Vol. 29, No. 2, 02.2008, p. 110-115.

Research output: Contribution to journalArticle

Di Luigi, L, Baldari, C, Pigozzi, F, Emerenziani, GP, Gallotta, MC, Iellamo, F, Ciminelli, E, Sgrò, P, Romanelli, F, Lenzi, A & Guidetti, L 2008, 'The long-acting phosphodiesterase inhibitor tadalafil does not influence athletes' V̇O2max, aerobic, and anaerobic thresholds in normoxia', International Journal of Sports Medicine, vol. 29, no. 2, pp. 110-115. https://doi.org/10.1055/s-2007-965131
Di Luigi, Luigi ; Baldari, C. ; Pigozzi, F. ; Emerenziani, G. P. ; Gallotta, M. C. ; Iellamo, F. ; Ciminelli, E. ; Sgrò, P. ; Romanelli, F. ; Lenzi, A. ; Guidetti, L. / The long-acting phosphodiesterase inhibitor tadalafil does not influence athletes' V̇O2max, aerobic, and anaerobic thresholds in normoxia. In: International Journal of Sports Medicine. 2008 ; Vol. 29, No. 2. pp. 110-115.
@article{4f7521ab24984c4f82ee0e582636cf36,
title = "The long-acting phosphodiesterase inhibitor tadalafil does not influence athletes' V̇O2max, aerobic, and anaerobic thresholds in normoxia",
abstract = "Whereas experimental studies showed that in healthy trained subjects, the phosphodiesterase-5 inhibitor (PDE-5i) sildenafil improves exercise capacity in hypoxia and not in normoxia, no studies on the effects of the long half-life PDE-5i tadalafil exist. In order to evaluate whether tadalafil influences functional parameters and performance during a maximal exercise test in normoxia, we studied 14 healthy male athletes in a double-blind cross-over protocol. Each athlete performed two tests on a cycle ergometer, both after placebo or tadalafil (at therapeutic dose: 20 mg) administration. Oxygen consumption (V̇O2), blood lactate, respiratory exchange ratio, rate of perceived exertion, arterial blood pressure (BP), heart frequency (HR) and oxygen pulse (V̇O2/HR) were evaluated before exercise, at individual ventilatory and anaerobic thresholds (IVT and IAT), at V̇O 2max and during recovery. Compared to placebo, a single tadalafil administration significantly reduced systolic BP before and after exercise (p <0.05), decreased V̇O2/HR at IVT (13.3 ± 1.8 vs. 14.5 ± 2.1 mL·beat-1; p = 0.03), but did not modify individual V̇O2max, IVT, or IAT. In healthy athletes, 20 mg of tadalafil does not substantially influence physical fitness-related parameters, exercise tolerance, and cardiopulmonary responses to maximal exercise in normoxia; it remains to be verified if higher doses/prolonged use influence health and/or sport performance in field conditions.",
keywords = "Doping, Erectile dysfunction, Exercise, Nitric oxide, PDE-5, Sport",
author = "{Di Luigi}, Luigi and C. Baldari and F. Pigozzi and Emerenziani, {G. P.} and Gallotta, {M. C.} and F. Iellamo and E. Ciminelli and P. Sgr{\`o} and F. Romanelli and A. Lenzi and L. Guidetti",
year = "2008",
month = "2",
doi = "10.1055/s-2007-965131",
language = "English",
volume = "29",
pages = "110--115",
journal = "International Journal of Sports Medicine",
issn = "0172-4622",
publisher = "Georg Thieme Verlag",
number = "2",

}

TY - JOUR

T1 - The long-acting phosphodiesterase inhibitor tadalafil does not influence athletes' V̇O2max, aerobic, and anaerobic thresholds in normoxia

AU - Di Luigi, Luigi

AU - Baldari, C.

AU - Pigozzi, F.

AU - Emerenziani, G. P.

AU - Gallotta, M. C.

AU - Iellamo, F.

AU - Ciminelli, E.

AU - Sgrò, P.

AU - Romanelli, F.

AU - Lenzi, A.

AU - Guidetti, L.

PY - 2008/2

Y1 - 2008/2

N2 - Whereas experimental studies showed that in healthy trained subjects, the phosphodiesterase-5 inhibitor (PDE-5i) sildenafil improves exercise capacity in hypoxia and not in normoxia, no studies on the effects of the long half-life PDE-5i tadalafil exist. In order to evaluate whether tadalafil influences functional parameters and performance during a maximal exercise test in normoxia, we studied 14 healthy male athletes in a double-blind cross-over protocol. Each athlete performed two tests on a cycle ergometer, both after placebo or tadalafil (at therapeutic dose: 20 mg) administration. Oxygen consumption (V̇O2), blood lactate, respiratory exchange ratio, rate of perceived exertion, arterial blood pressure (BP), heart frequency (HR) and oxygen pulse (V̇O2/HR) were evaluated before exercise, at individual ventilatory and anaerobic thresholds (IVT and IAT), at V̇O 2max and during recovery. Compared to placebo, a single tadalafil administration significantly reduced systolic BP before and after exercise (p <0.05), decreased V̇O2/HR at IVT (13.3 ± 1.8 vs. 14.5 ± 2.1 mL·beat-1; p = 0.03), but did not modify individual V̇O2max, IVT, or IAT. In healthy athletes, 20 mg of tadalafil does not substantially influence physical fitness-related parameters, exercise tolerance, and cardiopulmonary responses to maximal exercise in normoxia; it remains to be verified if higher doses/prolonged use influence health and/or sport performance in field conditions.

AB - Whereas experimental studies showed that in healthy trained subjects, the phosphodiesterase-5 inhibitor (PDE-5i) sildenafil improves exercise capacity in hypoxia and not in normoxia, no studies on the effects of the long half-life PDE-5i tadalafil exist. In order to evaluate whether tadalafil influences functional parameters and performance during a maximal exercise test in normoxia, we studied 14 healthy male athletes in a double-blind cross-over protocol. Each athlete performed two tests on a cycle ergometer, both after placebo or tadalafil (at therapeutic dose: 20 mg) administration. Oxygen consumption (V̇O2), blood lactate, respiratory exchange ratio, rate of perceived exertion, arterial blood pressure (BP), heart frequency (HR) and oxygen pulse (V̇O2/HR) were evaluated before exercise, at individual ventilatory and anaerobic thresholds (IVT and IAT), at V̇O 2max and during recovery. Compared to placebo, a single tadalafil administration significantly reduced systolic BP before and after exercise (p <0.05), decreased V̇O2/HR at IVT (13.3 ± 1.8 vs. 14.5 ± 2.1 mL·beat-1; p = 0.03), but did not modify individual V̇O2max, IVT, or IAT. In healthy athletes, 20 mg of tadalafil does not substantially influence physical fitness-related parameters, exercise tolerance, and cardiopulmonary responses to maximal exercise in normoxia; it remains to be verified if higher doses/prolonged use influence health and/or sport performance in field conditions.

KW - Doping

KW - Erectile dysfunction

KW - Exercise

KW - Nitric oxide

KW - PDE-5

KW - Sport

UR - http://www.scopus.com/inward/record.url?scp=39149117328&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=39149117328&partnerID=8YFLogxK

U2 - 10.1055/s-2007-965131

DO - 10.1055/s-2007-965131

M3 - Article

VL - 29

SP - 110

EP - 115

JO - International Journal of Sports Medicine

JF - International Journal of Sports Medicine

SN - 0172-4622

IS - 2

ER -